Invited Editorial
Vascular endothelial growth factor gene transfer for diabetic polyneuropathy†
John A. Kessler MD,
John A. Kessler MD
Department of Neurology, Northwestern University's Feinberg School of Medicine, Chicago, IL
Search for more papers by this authorJohn A. Kessler MD,
John A. Kessler MD
Department of Neurology, Northwestern University's Feinberg School of Medicine, Chicago, IL
Search for more papers by this author†
Potential conflict of interest: Nothing to report.
References
- 1 Said G. Diabetic neuropathy–a review. Nat Clin Pract Neurol 2007; 3: 331–340.
- 2 Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–986.
- 3 Martin CL, Albers J, Herman WH, et al; DCCT/EDIC Research Group. Neuropathy among the Diabetes Control and Complications Trial Cohort 8 years after trial completion. Diabetes Care 2006; 29: 340–344.
- 4 Ropper AH, Gorson KC, Gooch CL, et al. Vascular endothelial growth factor gene transfer for diabetic, polyneuropathy: A randomized, double-blinded trial. Ann Neuro 2009; 65: 386–393
- 5 Schratzberger P, Walter DH, Rittig K, et al. Reversal of experimental diabetic neuropathy by VEGF gene transfer. J Clin Invest 2001; 107: 1083–1092.
- 6 Veves A, King GL. Can VEGF reverse diabetic neuropathy in human subjects? J Clin Invest 2001; 107: 1215–1218.
- 7 Apfel SC. Neurotrophic factors and diabetic peripheral neuropathy. Eur Neurol 1999; 41(suppl 1): 27–34.
- 8 Nigel A, Calcutt NA, Jolivalt CG, Fernyhough P. Growth factors as therapeutics for diabetic neuropathy. Curr Drug Targets 2008; 9: 47–59.
- 9
Fernyhough P,
Diemel, LT,
Hardy J. et al.
Altered neurotrophin mRNA levels in peripheral nerve and skeletal muscle of experimentally diabetic rats.
Eur J Neurosci
1995;
7:
1107–1110.
10.1111/j.1460-9568.1995.tb01098.x Google Scholar
- 10 Schmidt, RE, Plurad, SB, Saffitz, et al. Retrograde axonal transport of 125I-nerve growth factor in rat ileal mesenteric nerves. Effect of streptozocin diabetes. Diabetes 1985; 34: 1230–1240.
- 11 Hellweg R, Raivich G, Hartung HD, et al. Axonal transport of endogenous nerve growth factor (NGF) and NGF receptor in experimental diabetic neuropathy. Exp Neurol 1994; 130: 24–30.
- 12 Mizisin AP, DiStefano PS, Liu X, et al. Decreased accumulation of endogenous brain-derived neurotrophic factor against constricting sciatic nerve ligatures in streptozotocin-diabetic and galactose-fed rats. Neurosci Lett 1999; 263: 149–152.
- 13 Wuarin L, Guertin DM, Ishii DN. Early reduction in insulin-like growth factor gene expression in diabetic nerve. Exp Neurol 1994; 130: 106–114.
- 14 Schmidt RE, Dorsey DA, Beaudet LN, Peterson RG. Analysis of the Zucker Diabetic Fatty (ZDF) type 2 diabetic rat model suggests a neurotrophic role for insulin/IGF-I in diabetic autonomic neuropathy. Am J Pathol 2003; 163: 21–28.
- 15 Apfel SC, Kessler JA, Adornato BT, et al. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group. Neurology 1998; 51: 695–702.
- 16 Apfel SC, Schwartz S, Adornato BT, et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. rhNGF Clinical Investigator Group. JAMA 2000; 284: 2215–2221.
- 17 Apfel SC. Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold? Int Rev Neurobiol 2002; 50: 393–413.
- 18 Wellmer A, Misra VP, Sharief MK, et al. A double-blind placebo-controlled clinical trial of recombinant human brain-derived neurotrophic factor (rhBDNF) in diabetic polyneuropathy. J Peripher Nerv Syst 2001; 6: 204–210.
- 19 Fagerberg SE. Diabetic neuropathy, a clinical and histological study on the significance of vascular affection. Acta Med Scand Suppl 1959; 345: 1–97.
- 20 Cameron NE, Eaton SE, Cotter MA, Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 2001; 44: 1973–1988.
- 21 Tesfaye S, Harris N, Jakubowski JJ, et al. Impaired blood flow and arterio-venous shunting in human diabetic neuropathy: a novel technique of nerve photography and fluorescein angiography. Diabetologia 1993; 36: 1266–1274.
- 22 Rosenstein JM, Mani N, Khaibullina A, Krum JM. Neurotrophic effects of vascular endothelial growth factor on organotypic cortical explants and primary cortical neurons. J Neurosci 2003; 23: 11036–11044.
- 23 Sondell M, Lundborg G, Kanje M. Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J Neurosci 1999; 19: 5731–5740.
- 24 Sondell M, Sundler F, Kanje M. Vascular endothelial growth factor is a neurotrophic factor which stimulates axonal outgrowth through the flk-1 receptor. Eur J Neurosci 2000; 12: 4243–4254.
- 25 Murakami T, Arai M, Sunada Y, Nakamura A. VEGF 164 gene transfer by electroporation improves diabetic sensory neuropathy in mice. J Gene Med 2006; 8: 773–781.
- 26 Freedman SB, Vale P, Kalka C, et al. Plasma vascular endothelial growth factor (VEGF) levels after intramuscular and intramyocardial gene transfer of VEGF-1 plasmid DNA. Hum Gene Ther 2002; 13: 1595–1603.
Citing Literature
